Mohammed Jahanzeb, MD explains the design of the study examining real-world treatment patterns and outcomes in U.S. ALK+ NSCLC patients receiving immuno-oncology therapy.
Advertisement
Outcomes in ALK+ NSCLC Patients Receiving Immuno-Oncology Therapy
